series-a
Stage
1
Investors
About
Stylus Medicine develops in vivo genetic medicines using engineered recombinases to insert therapeutic payloads into safe harbor sites in the human genome, primarily focusing on creating precise in vivo CAR-T therapies delivered via cell-targeted lipid nanoparticles.
Explore Stylus Medicine's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.